2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†
Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2019, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeExcess blastsRefractory anemiaOverall survival benefitRetrospective cohort studyMedian OSOS benefitRAEB patientsCohort studySurvival benefitTherapy useMyelodysplastic syndromeClinical trialsLower riskMedicare dataPatientsPropensity scoreOlder adultsDiagnosisAnemiaQuartileUnited StatesAssociationEnd resultOSAssociation of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeOverall survivalHMA cyclesHMA therapyProvider experienceCox proportional hazards modelOlder MDS patientsMedian overall survivalPercent of patientsSEER-Medicare dataMultivariate logistic regressionProportional hazards modelHMA initiationClinical outcomesMDS patientsClinical trialsMedian numberHMA treatmentHazards modelPatientsSignificant associationLogistic regressionPopulation-level survivalSurvivalSyndrome
2018
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States
Ma X, Steensma DP, Scott BL, Kiselev P, Sugrue MM, Swern AS. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. BMJ Open 2018, 8: e019955. PMID: 30037860, PMCID: PMC6059277, DOI: 10.1136/bmjopen-2017-019955.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnemiaAzacitidineDatabases, FactualDecitabineElectronic Health RecordsEnzyme InhibitorsFemaleHematinicsHumansImmunologic FactorsIron Chelating AgentsLenalidomideMaleMiddle AgedMultivariate AnalysisMyelodysplastic SyndromesProportional Hazards ModelsRecurrenceRetrospective StudiesThalidomideTreatment OutcomeUnited StatesConceptsDisease-modifying therapiesErythropoiesis-stimulating agentsElectronic medical record databaseMyelodysplastic syndromeMedical record databasePatient characteristicsTreatment patternsGE Centricity Electronic Medical Records databaseRecord databaseLow baseline hemoglobin levelMultivariable Cox regression modelsLarge electronic medical record databaseBaseline hemoglobin levelAbsence of comorbiditiesFirst-line treatmentMajority of patientsSelection of patientsCox regression modelIron chelation therapyAgent azacitidineMore comorbiditiesHemoglobin levelsMale genderClinical trialsChelation therapy
2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal Of Haematology 2016, 175: 829-840. PMID: 27650975, DOI: 10.1111/bjh.14305.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeRAEB patientsMedian survivalClinical trialsMultivariate Cox proportional hazards modelCox proportional hazards modelKaplan-Meier methodPopulation-based survivalSignificant survival differenceComparative clinical effectivenessProportional hazards modelAgent azacitidineHMA initiationExcess blastsOlder patientsRandomized trialsHistological subtypesRefractory anemiaClinical effectivenessSurvival differencesSubset analysisSurvival advantageHazards modelPatientsDecitabine
2015
Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS)
Ma X, Swern A, Kiselev P, Fliss A, Lu J, Scott B, Steensma D, Sugrue M. Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS). Blood 2015, 126: 3319. DOI: 10.1182/blood.v126.23.3319.3319.Peer-Reviewed Original ResearchDiagnosis of MDSICD-9-CM codesReal-world cohortMyelodysplastic syndromeActive treatmentEMR databaseFinal cohortInitial cohortCelgene CorporationBaseline characteristicsSupportive careSupportive treatmentTreatment patternsClinical trialsSEER programInclusion criteriaReal-world clinical practiceElectronic medical record databaseClinical Modification codesPopulation-based surveillanceEnd Results ProgramPrimary care physiciansCancer outcomes researchBone marrow aspirateClinical practice dataComparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood 2015, 126: 3285. DOI: 10.1182/blood.v126.23.3285.3285.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeHR-MDS patientsKaplan-Meier survival curvesEnd of studyHMA initiationMedian OSClinical trialsComorbidity countHazard ratioHigh school educationClinical practiceMultivariate Cox proportional hazards modelSurvival curvesEnd Results-Medicare databaseMedian household incomeRandomized phase III trialReal-world clinical practiceCox proportional hazards modelOlder MDS patientsDisability Status ScoreRetrospective cohort studyOverall survival advantagePhase III trialsYear of diagnosisErythropoiesis-stimulating agents